UVA Irradiation Enhances Brusatol‐Mediated Inhibition of Melanoma Growth by Downregulation of the Nrf2‐Mediated Antioxidant Response
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Brusatol (BR) is a potent inhibitor of Nrf2, a transcription factor that is highly expressed in cancer tissues and confers chemoresistance. UVA‐generated reactive oxygen species (ROS) can damage both normal and cancer cells and may be of potential use in phototherapy. In order to provide an alternative method to treat the aggressive melanoma, we sought to investigate whether low‐dose UVA with BR is more effective in eliminating melanoma cells than the respective single treatments. We found that BR combined with UVA led to inhibition of A375 melanoma cell proliferation by cell cycle arrest in the G1 phase and triggers cell apoptosis. Furthermore, inhibition of Nrf2 expression attenuated colony formation and tumor development from A375 cells in heterotopic mouse models. In addition, cotreatment of UVA and BR partially suppressed Nrf2 and its downstream target genes such as HO‐1 along with the PI3K/AKT pathway. We propose that cotreatment increased ROS‐induced cell cycle arrest and cellular apoptosis and inhibits melanoma growth by regulating the AKT‐Nrf2 pathway in A375 cells which offers a possible therapeutic intervention strategy for the treatment of human melanoma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method
Livak, K. J., & Schmittgen, T. D. (2001) · Methods · doi:10.1006/meth.2001.1262 · Cited by 180,860
Activation of Nrf2-antioxidant signaling attenuates NFκB-inflammatory response and elicits apoptosis
Li, W., Khor, T. O., Xu, C., Shen, G., Jeong, W.-S., Yu, S., & Kong, A.-N. (2008) · Biochemical Pharmacology · doi:10.1016/j.bcp.2008.07.017 · Cited by 738 · cited 1×
“It was previously reported that Nrf2 and NF-κB simultaneously accumulate in the cell nucleus and NF-κB (p65) antagonizes Nrf2-induced gene transcription [42].”
BackgroundSelf-citationShibata, T., Ohta, T., Tong, K. I., Kokubu, A., Odogawa, R., Tsuta, K., Asamura, H., Yamamoto, M., & Hirohashi, S. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0806268105 · Cited by 728
Toward clinical application of the Keap1-Nrf2 pathway
Suzuki, T., Motohashi, H., & Yamamoto, M. (2013) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2013.04.005 · Cited by 680 · cited 1×
“Under oxidative stress conditions including chemicals, UV irradiation, and heat shock, Nrf2 binding to its upstream keap1 (Kelch-like erythroid cell-derived protein with CNC homology- (ECH-) associated protein 1) is disrupted and leads to Nrf2 nuclear translocation and consequently activates expression of cytoprotecti…”
BackgroundBrusatol enhances the efficacy of chemotherapy by inhibiting the Nrf2-mediated defense mechanism
Ren, D., Villeneuve, N. F., Jiang, T., Wu, T., Lau, A., Toppin, H. A., & Zhang, D. D. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1014275108 · Cited by 673
Oncogenic KRAS Confers Chemoresistance by Upregulating NRF2
Tao, S., Wang, S., Moghaddam, S. J., Ooi, A., Chapman, E., Wong, P. K., & Zhang, D. D. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-1439 · Cited by 291
Redox activation of Nrf2 & NF-κB: A double end sword?
Buelna-Chontal, M., & Zazueta, C. (2013) · Cellular Signalling · doi:10.1016/j.cellsig.2013.08.007 · Cited by 239 · cited 1×
“Conversely, some phase II-inducers (enzyme) activate the signaling and inhibit NF-κB pathway [43].”
BackgroundOlayanju, A., Copple, I. M., Bryan, H. K., Edge, G. T., Sison, R. L., Wong, M. W., Lai, Z.-Q., Lin, Z.-X., Dunn, K., Sanderson, C. M., et al. (2015) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2014.11.003 · Cited by 232
Zhu, J., Wang, H., Chen, F., Fu, J., Xu, Y., Hou, Y., Kou, H. H., Zhai, C., Nelson, M. B., Zhang, Q., et al. (2016) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2016.09.010 · Cited by 162
Reelfs, O., Xu, Y.-Z., Massey, A., Karran, P., & Storey, A. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-0166 · Cited by 30
Cited by
Emanuelli, M., Sartini, D., Molinelli, E., Campagna, R., Pozzi, V., Salvolini, E., Simonetti, O., Campanati, A., & Offidani, A. (2022) · Antioxidants · doi:10.3390/antiox11040612 · Cited by 132
Oxidative Stress-Related Mechanisms in Melanoma and in the Acquired Resistance to Targeted Therapies
Pizzimenti, S., Ribero, S., Cucci, M. A., Grattarola, M., Monge, C., Dianzani, C., Barrera, G., & Muzio, G. (2021) · Antioxidants · doi:10.3390/antiox10121942 · Cited by 79
Nrf2/P–glycoprotein axis is associated with clinicopathological characteristics in colorectal cancer
Sadeghi, M. R., Jeddi, F., Soozangar, N., Somi, M. H., Shirmohamadi, M., Khaze, V., & Samadi, N. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.05.062 · Cited by 44
Metadata
- Authors
- Wang, M., Shi, G., Bian, C., Nisar, M. F., Guo, Y., Wu, Y., Li, W., Huang, X., Jiang, X., Bartsch, J. W., Ji, P., & Zhong, J. L.
- Venue
- Oxidative Medicine and Cellular Longevity
- Publisher
- Wiley
- Published
- 2018-01
- Volume
- 2018
- Issue
- 1
- Pages
- 9742154-9742154
- ISSN
- 1942-0994 (ISSN-L)
- 1942-0900
- OpenAlex
- W2794159870
- Cited by
- 49
- References
- 10
- FWCI
- 1.49
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.